论文部分内容阅读
目的探讨肺癌患者血清中恶性肿瘤相关物质TSGF、NSE和CYFRA21-1的水平及其临床意义。方法用电化学发光免疫法(ECLIA)检测210例肺癌患者、44例肺良性疾病患者及112例健康对照血清NSE和CYFRA21-1水平,同时用光电比色法检测其血清TSGF水平。结果与肺良性疾病组及健康对照组相比,肺癌患者血清中3项标志物的水平明显升高(P<0.05)。3项标志物的水平和敏感性与病理类型、非小细胞肺癌(NSCLC)临床分期及淋巴结转移有关(P<0.05)。TSGF、NSE及CYFRA21-1判别肺癌血清的敏感性分别为60.0%、38.1%和59.5%,特异性分别为92.9%、93.6%和96.8%,3项标志物联合检测判别肺癌血清的敏感性和特异性分别为87.6%和84.0%。治疗前及治疗后无效组患者血清3项标志物的水平均明显高于治疗后有效组(P<0.05)。结论血清TSGF、NSE及CYFRA21-1联合检测在肺癌诊断、病情监测及疗效判断方面具有较重要的临床价值,三者联合检测可明显提高肺癌诊断的敏感性。
Objective To investigate the serum levels of TSGF, NSE and CYFRA21-1 in serum of patients with lung cancer and their clinical significance. Methods Serum levels of NSE and CYFRA21-1 in 210 patients with lung cancer, 44 patients with benign pulmonary disease and 112 healthy controls were detected by electrochemiluminescence immunoassay (ECLIA). Meanwhile, serum TSGF level was detected by electrochromic assay. Results Compared with benign lung disease group and healthy control group, the serum levels of three markers of lung cancer patients were significantly increased (P <0.05). The level and sensitivity of the three markers were correlated with the pathological type, clinical stage and lymph node metastasis of non-small cell lung cancer (NSCLC) (P <0.05). The sensitivities of TSGF, NSE and CYFRA21-1 in distinguishing lung cancer serum were 60.0%, 38.1% and 59.5%, respectively, and their specificity were 92.9%, 93.6% and 96.8%, respectively. The specificity was 87.6% and 84.0% respectively. The serum levels of three markers in patients before and after treatment were significantly higher than those in the effective group after treatment (P <0.05). Conclusion The combined detection of serum TSGF, NSE and CYFRA21-1 has important clinical value in the diagnosis of lung cancer, the monitoring of disease and the judgment of curative effect. The combined detection of the three can obviously improve the sensitivity of lung cancer diagnosis.